Products

Mindpeak Breast
Mindpeak
Oncology AI
Mindpeak offers AI-driven image analysis solutions for breast pathology, aiming to standardize interpretation and reduce variability in biomarker analysis. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results.

See all 1 product →

About Mindpeak

Mindpeak is a pioneering healthcare AI company that develops cutting-edge artificial intelligence and deep learning solutions for digital pathology, primarily focused on enhancing cancer diagnostics. Their technology assists pathologists in routine diagnostics by automating the analysis of tissue images, including H&E, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) stains. This automation aims to provide faster, more accurate, and reproducible results, freeing specialists from tedious, repetitive tasks such as the quantification of cells or biomarkers, allowing them to concentrate on tasks requiring their unique human expertise.

The company’s AI algorithms are designed to extract precise, actionable insights from tissue images, supporting everything from subcellular biomarker quantification to predictive patient stratification. Mindpeak’s solutions are integrated into clinical workflows, with some of their AI-based diagnostic tools for breast cancer analysis (e.g., BreastIHC) already in routine clinical use in the US and EU. Beyond clinical labs, biopharmaceutical companies also leverage Mindpeak’s AI technology to predict the effectiveness of certain medications in cancer therapy and to enable targeted treatments, thereby bridging innovation and clinical impact in both routine diagnostics and biomarker development.

Focus Areas

AI-powered digital pathology cancer diagnostics automated tissue analysis biomarker quantification precision medicine deep learning oncology

Business Intelligence

TechnologyProprietary AI technology, deep learning models, explainable AI (xAI), hybrid deep learning technique, "IHC-first" foundation model, cloud-native (implied by integrations and global deployment)

What Physicians Need to Know

AI-Powered Digital Pathology
Mindpeak develops automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning, transforming tissue into high-dimensional data. Their solutions provide instant, pixel-level analysis of digital images of tissue samples.
Cancer Diagnostics & Automated Tissue Analysis
Mindpeak specializes in AI-driven cancer diagnostics, offering solutions for breast cancer (HER2, Ki-67, ER, PR, p53), lung cancer (PD-L1), and prostate cancer. Their tools automate tedious and repetitive tasks like cell and biomarker quantification, freeing up specialists.
Biomarker Quantification & Precision Medicine
The company enables the discovery of AI-driven biomarkers that guide targeted therapies and power precision medicine. Their AI decodes complex biological patterns invisible to the human eye, unlocking predictive signals for patient response to therapy.
Deep Learning & Oncology
Mindpeak utilizes proprietary clinical-grade deep learning architectures tailored to pathology, achieving results on par with human experts. Their focus is on oncology, providing solutions that enhance diagnostic confidence and efficiency in cancer care.
Key Differentiators
Mindpeak's key differentiators include '0-click' AI solutions that require no manual fine-tuning for various labs and staining protocols, ensuring immediate readiness for use. Their technology is built for clinical routine and regulatory oversight, with certifications reflecting a focus on safety, reproducibility, and global deployment. They offer robust, reproducible AI that performs in real laboratories and meets regulatory standards.
Technology Stack
Mindpeak's technology stack is built on state-of-the-art artificial intelligence and deep learning, specifically proprietary clinical-grade deep learning architectures. They leverage a 'hybrid deep learning technique' and an 'IHC-first' foundation model. Their solutions deliver instant, pixel-level analysis of digital images and can operate without cloud connectivity, ensuring data privacy and security.
Physician Tip

For physicians, Mindpeak's AI solutions offer several advantages. They can significantly reduce the time needed per case, leading to faster turnaround times for diagnoses. The AI provides reproducible results, minimizing inter-observer variability and supporting confident clinical decisions. By automating tedious tasks like cell and biomarker quantification, pathologists can focus their human expertise on more complex diagnostic challenges. The '0-click' nature of their solutions means minimal setup and immediate integration into existing workflows, enhancing lab productivity and diagnostic consistency. Furthermore, the combination of human experts with Mindpeak's AI can lead to accuracies beyond current standards.

Mindpeak's algorithms are designed for deep integration into the pathologist's workflow within partner software, aiming for a 'true 0-click-solution'. They also offer access through the Mindpeak AI Console. Mindpeak has established partnerships with leading digital pathology platforms and companies, including Gestalt Diagnostics (PathFlow platform), Paige (FullFocusu00ae viewer), Sectra (Amplifier Marketplace), Techcyte (Fusionu2122 Partner Program), and Leica Biosystems (Aperio HALO AP platform and Aperio AI Store). These collaborations ensure seamless workflow integration, streamlined data exchange, and expanded access to their AI solutions within various digital pathology ecosystems.

Products by Mindpeak

1 product in the directory

Mindpeak Breast
Mindpeak
Oncology AI
Mindpeak offers AI-driven image analysis solutions for breast pathology, aiming to standardize interpretation and reduce variability in biomarker analysis. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results.

What the Web Says

Mindpeak is a company that develops AI-based visual diagnosis platforms to assist pathologists in identifying and quantifying tumorous regions and detecting cancer cells, aiming for faster, more accurate, and reproducible diagnoses. Their products focus on analyzing IHC slides for lung and breast cancers. While specific product and employer reviews for Mindpeak are limited on major review platforms like G2, Glassdoor, Capterra, and Reddit, the company is actively partnering with other digital pathology solution providers to integrate its AI algorithms.

Overall: Mixed

Strengths

  • AI-powered solutions for faster and more accurate cancer diagnosis.
  • Focus on quantitative immunohistochemistry (IHC) products for lung and breast cancers.
  • Integration with established digital pathology platforms like Paige Platform.
  • Aims to make microscopical analysis accessible and cost-effective.
  • Emphasis on safety, reproducibility, and global deployment of technology.
  • Deliberate interview process to find the right fit for both the company and candidates.

Limitations

  • Limited readily available product reviews on major platforms like G2, Glassdoor, Capterra, and Reddit.
  • Scam Detector gave mindpeak.ai a low trust score (14.4/100) due to suspicious activity and a newly registered domain, though this could be a mischaracterization given the company's established partnerships and funding.
  • No current internship opportunities available.
  • Lack of detailed employee reviews on common platforms makes it difficult to assess company culture and work-life balance.

Based on reviews from: Capterra, HealthAIdir, Scam Detector, G2, Paige and Mindpeak Launch an Integrated Solution for Enhanced Cancer Diagnosis - Business Wire, PitchBook, Mindpeak Website (mindpeak.ai), Indeed.com

Last updated: 2026-10-13

Videos

News, demos, and interviews about Mindpeak.

Loading videos...

Videos load interactively. If none appear, search YouTube for Mindpeak →

View all on YouTube

Press & Coverage

Mindpeak
Mindpeak Earns IVDR Certification, Reinforcing Its Commitment to Quality and Regulatory Excellence
Mindpeak has achieved certification under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR), validating its quality management system and meeting the EU's rigorous standards for cancer-related diagnostic devices. This milestone reinforces the company's commitment to quality and regulatory excellence in AI-powered digital pathology.
2026-09
GlobeNewswire
Mindpeak and Revolune Announce Commercial Co-Selling Partnership to Deliver End-to-End Spatial Biology Solutions
Mindpeak and Revolune have partnered to offer an integrated workflow combining multiplex tissue staining with AI-powered image analysis, aiming to streamline spatial biology solutions for researchers. This collaboration combines Mindpeak's PhenoScout™ AI platform with Revolune's multiplex IF kits.
2026-09
Leica Biosystems
Mindpeak Announces Global Reseller Agreement with Leica Biosystems to Expand Access to AI Pathology Solutions
Mindpeak and Leica Biosystems have entered a global reseller agreement, making Mindpeak's AI applications available through Leica Biosystems' digital pathology ecosystem. This partnership aims to expand global access to AI-powered pathology analysis for laboratories and research teams.
2026-03
Business Wire
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics
Epredia and Mindpeak have signed a distribution agreement to bring Mindpeak's AI-based image recognition software to Epredia's digital pathology customers in the European Union. This collaboration aims to accelerate processes and reduce costs in pathology laboratories.
2026-02
GlobeNewswire
Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology
Mindpeak has been granted its first patent for a novel method of training AI systems to accurately identify and classify cell types in tissue samples for medical diagnosis. This patent, issued across 18 EU member states and validated in the UK, is a significant milestone for advancing AI-powered pathology.
2025-12
Mindpeak
Enhancing HER2 IHC Interpretation in Breast Cancer with AI Assistance: Focus on Ultralow Expression in a Multicenter Study across Asia
A multinational study demonstrated that AI-assisted HER2 IHC interpretation improves pathologist accuracy, reproducibility, and efficiency, particularly in challenging HER2 low and ultralow categories. This suggests AI can enhance personalized treatment decision-making for HER2-targeted therapies.
2025-12
Mindpeak
PathGroup Chooses Mindpeak to Power Its Digital Pathology Transformation
Mindpeak has announced a strategic collaboration with PathGroup, a leading provider of pathology services, to accelerate the adoption of AI-driven pathology. This partnership will integrate Mindpeak's image analysis technology with PathGroup's diagnostic network, starting with Breast Suite and PD-L1 AI solutions.
2025-11
Mindpeak
Mindpeak's AI in npj precision oncology
Results of a large-scale study on Gastric PD-L1 scoring, involving Mindpeak's IHC foundation model and expert pathologists, have been published in npj Precision Oncology. The study highlights the role of AI in advancing personalized cancer care and addressing challenges in biomarker testing.
2025-05

Frequently Asked Questions

Mindpeak offers a suite of AI-powered solutions for cancer diagnostics, including applications for breast cancer (HER2, Ki-67, ER/PR, p53), lung cancer (PD-L1), and prostate cancer. Their 'Pan-Tumor PD-L1 Suite' provides standardized PD-L1 quantification across various solid tumors, and they also offer H&E-based image analysis for prostate, breast, and macrodissection workflows.
Mindpeak's AI solutions undergo structured validation across multiple clinical sites and are continuously monitored in real-world environments to ensure reliability and reproducibility. They utilize a hybrid deep learning approach and focus on scalable 'Frontier Model AI' built for regulated environments, emphasizing validation and long-term integration.
Mindpeak operates within regulated clinical environments and maintains a formal quality management system. Their diagnostic products are CE-IVD certified, and the company operates under an ISO 13485 certified quality management system.
Mindpeak's software is designed to integrate seamlessly with established digital pathology infrastructures and image management systems, supporting scalable deployment across laboratory networks. They offer '0-click' solutions that integrate directly into partner software like Roche's navifyu00ae Digital Pathology and Leica Biosystems' Aperio digital pathology ecosystem, aiming to streamline workflows without disrupting routine clinical practice.
Mindpeak supports secure deployment models and complies with industry-standard data protection and IT security requirements. Their AI technology can deliver analysis without requiring cloud connectivity, offering data privacy and security for both clinical and research environments.
Mindpeak offers an AI-native training platform called peakAcademy, which supports standardized and reproducible biomarker assessment. They also collaborate with partners like Discovery Life Sciences to provide AI-enabled pathology workflows and pathologist training.
Mindpeak, founded in 2018, is a global innovator in AI-driven digital pathology solutions. They raised $15.3 million in a Series A funding round in September 2024, led by ZEISS Ventures and InnoVentureFund. Key partners include Roche, Leica Biosystems, PathGroup, Proscia, and Epredia, among others, facilitating the integration and distribution of their AI algorithms.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.